One of the key concepts born out of the COVID-19 pandemic is the 100 Days Mission, an initiative endorsed by the Group of Seven major economies and the Group of 20 industrialized and emerging-market nations whose goal is to have effective diagnostics, treatments, and vaccines within 100 days of a public health emergency declaration.
But a new report reveals serious gaps in the clinical pipeline for diseases with pandemic potential, and limited investments in their research and development over the years.
There are no approved treatments and very few in clinical trials for diseases with high fatality rates, such as Marburg and Nipah. There are also no diagnostics in late-stage clinical development for Zika and SARS.
Read more:
► 'Just break the glass’ — Inside CEPI’s 100-day plan for a new vaccine
► Exclusive: Vaccine org CEPI under pressure to share pricing agreements
► Opinion: Climate-driven pandemics are coming. Will we be ready?
About the author
Jenny Lei Ravelo@JennyLeiRavelo
Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.
